Actively Recruiting
Evaluation of ARC-02 Safety, Tolerability, and Activity in Adults with B-cell Non-Hodgkin Lymphoma
Led by Taiho Oncology, Inc. · Updated on 2026-11-02
140
Participants Needed
28
Research Sites
99 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ARC-02 for adults with B-cell Non-Hodgkin Lymphoma NHL, including various types such as follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma. This Phase 1 study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and early effectiveness of ARC-02 in participants who have previously received at least two lines of systemic therapies and have disease requiring treatment. Participants will receive ARC-02 through intravenous infusion on Day 1 of each cycle until their disease worsens or unacceptable side effects occur. The study includes multiple dose levels of ARC-02 alone or combined with rituximab, with dosing determined during dose escalation phases. There are four groups ARC-02 monotherapy dose escalation, ARC-02 monotherapy dose expansion, ARC-02 combined with rituximab dose escalation, and ARC-02 combined with rituximab dose expansion. During the study, participants will be monitored for dose-limiting toxicities, treatment-emergent adverse events, and serious adverse events over a period of up to five years. Researchers will evaluate response rates, time to response, duration of response, progression-free survival, and various pharmacokinetic measures. Participants will have regular assessments to track safety and clinical activity throughout the treatment and follow-up period, which may last several years.
CONDITIONS
Brief Title
A Study of ARC-02 in B-cell NHL
Research Team
T
Taiho Oncology, Inc.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here